Lupin receives final approval for malaria drug hydroxychloroquine sulfate tablets
Pharmaceutical company Lupin has said that they have received the final approval from the US Food and Drug Administration (USFDA) for Hydroxychloroquine Sulfate tablets indicated for the treatment of malaria.
This drug is prescribed for the treatment of malaria as well as for acute and chronic rheumatoid arthritis in adults. Hydroxychloroquine Sulfate tablets is a generic version of Concordia Pharmaceuticals, Inc’s Plaquenil tablets. Hydroxychloroquine Sulfate tablets had annual sales of around US$215.3 million in the US, according to IQVIA MAT April 2018 data.
Despite this development, the share was trading at Rs. 903.15 per share, down by 0.92 per cent at 11:16 IST. Its intraday high is recorded at Rs. 921 and intraday low is Rs. 902 per share on the BSE. Its 52-week high is Rs.1,229 and 52-week low is Rs.723.65 on the BSE.
At 11:16 hours, BSE Sensex was trading at 36,161.77 level, up by 0.64 per cent and Nifty50 was trading at 10,920.05 level, up by 0.62 per cent.